



(12) Translation of
European patent specification

(11) NO/EP 3154983 B1

NORWAY

(19) NO
(51) Int Cl.
C07D 491/052 (2006.01)
A61K 31/4188 (2006.01)
A61P 31/00 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2020.03.30
(80)	Date of The European Patent Office Publication of the Granted Patent	2020.02.12
(86)	European Application Nr.	15730621.8
(86)	European Filing Date	2015.06.08
(87)	The European Application's Publication Date	2017.04.19
(30)	Priority	2014.06.11, US, 201462010919 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(73)	Proprietor	Gilead Pharmasset LLC, 333 Lakeside Drive, Foster City, CA 94404, USA
(72)	Inventor	LAPINA, Olga, Viktorovna, c/o Gilead Sciences Inc.333 Lakeside Drive, Foster City, CA 94404, USA SHI, Bing, c/o Gilead Sciences Inc.333 Lakeside Drive, Foster City, CA 94404, USA WANG, Fang, c/o Gilead Sciences Inc.333 Lakeside Drive, Foster City, CA 94404, USA WOLCKENHAUER, Scott, Alan, c/o Gilead Sciences Inc.333 Lakeside Drive, Foster City, CA 94404, USA
(74)	Agent or Attorney	OSLO PATENTKONTOR AS, Hoffsvæien 1A, 0275 OSLO, Norge

(54) Title **SOLID FORMS OF AN ANTIVIRAL COMPOUND**

(56) References
Cited:

WO-A1-2013/075029
CAIRA: "Crystalline Polymorphism of Organic Compounds", TOPICS IN CURRENT CHEMISTRY,
SPRINGER, BERLIN, DE, vol. 198, 1 January 1998 (1998-01-01), pages 163-208, XP008166276, ISSN:
0340-1022
ANDERSON ET AL: "TOOLS FOR PURIFYING THE PRODUCT: COLUMN CHROMATOGRAPHY,
CRYSTALLIZATION AND RESLURRYING", PRACTICAL PROCESS RESEARCH AND DEVELOPMENT,
ACADEMIC PRESS, SAN DIEGO, US, 1 January 2000 (2000-01-01), pages 223-247, XP002382432,
RICHARD J BASTIN ET AL: "Salt Selection and Optimisation Procedures for Pharmaceutical New Chemical
Entities", ORGANIC PROCESS RESEARCH AND DEVELOP, AMERICAN CHEMICAL SOCIETY, US, vol.
4, no. 5, 19 July 2000 (2000-07-19), pages 427-435, XP008154792, ISSN: 1083-6160, DOI:
10.1021/OP000018U [retrieved on 2000-07-19]

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Krystallinsk metyl {(2S)-1-[(2S,5S)-2-(9-{2-[(2S,4S)-1-{(2R)-2-
[(metoksykarbonyl)amino]-2-fenylacetyl}-4-(metoksymetyl)pyrrolidin-2-yl]-1H-
imidazol-5-yl}-1,11-dihydroisokromeno[4',3':6,7]nafto[1,2-d]imidazol-2-yl)-5-
5 metylpyrrolidin-1-yl]-3-metyl-1-oksobutan-2-yl}karbamatfosfat (Forbindelse I
Fosfatform XII) karakterisert ved et røntgenpulverdiffraktogram omfattende
følgende topper: 3,8, 7,5 og 16,9 °2θ ± 0,2 °2θ, bestemt på et diffraktometer ved
bruk av Cu-Kα-stråling med en bølgelengde på 1.5406 Å.
- 10 2. Forbindelse I fosfatform XII ifølge krav 1, hvor diffraktogrammet videre
omfatter topper ved 8,5, 10,0 og 12,4 °2θ ± 0,2 °2θ.
3. Forbindelse I fosfatform XII ifølge krav 1 eller krav 2, karakterisert ved en
differensial skanning kalorimetri (DSC)-kurve som omfatter en endoterm ved
15 omtrent 205°C og en endoterm ved ca. 229°C.
4. Krystallinsk metyl {(2S)-1-[(2S,5S)-2-(9-{2-[(2S,4S)-1-{(2R)-2-
[(metoksykarbonyl)amino]-2-fenylacetyl}-4-(metoksymetyl)pyrrolidin-2-yl]-1H-
imidazol-5-yl}-1,11-dihydroisokromeno[4',3':6,7]nafto[1,2-d]imidazol-2-yl)-5-
20 metylpyrrolidin-1-yl]-3-metyl-1-oksobutan-2-yl}karbamatfosfat (Forbindelse I
Fosfatform XIV) karakterisert ved et røntgenpulverdiffraktogram omfattende
følgende topper: 3,5 og 6,9 °2θ ± 0,2 °2θ, som bestemt på et diffraktometer ved
bruk av Cu- Kα-stråling med en bølgelengde på 1.5406 Å.
- 25 5. Forbindelse I fosfatform XIV ifølge krav 4, hvor diffraktogrammet videre
omfatter topper ved 8,3 og 12,0 °2θ ± 0,2 °2θ.